Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical ...

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Primary myelofibrosis is a rare bone marrow blood cancer that disrupts the production of blood cells. This results in extramedullary hematopoiesis in other parts of the body, most notably the spleen, ...

Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...

Canada NewsWire MISSISSAUGA, ON, Nov. 12, 2024 MISSISSAUGA, ON, Nov. 12, 2024 /CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment o ...

MOMENTUM was a phase III, global, multicentre, randomised, double-blind study investigating momelotinib versus danazol in patients with myelofibrosis who were symptomatic and anemic and had been ...

The Haematological Malignancy Research Network estimate the prevalence of myelofibrosis in the UK to be 3.2 per 100,000 and the incidence is 0.6 per 100,000. This equates to 277 adults diagnosed with ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed following treatment with a type I JAK2 inhibitor. A phase 1 clinical trial ...

Algert Global LLC raised its holdings in shares of Geron Co. (NASDAQ:GERN – Free Report) by 210.9% during the third quarter, ...

Credit: Magda Wygralak via Shutterstock. Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia.